Selecting Among Preferred 1L Regimens — A Discussion
Published: | Updated:
New data show amivantamab+lazertinib boosts survival vs osimertinib in EGFR lung cancer, with Q4W subcutaneous dosing and side-effect tips.
Sarah Goldberg, MD, MPH
Advertisement
Articles by Sarah Goldberg, MD, MPH
Clinical Context & MARIPOSA Efficacy in 1L EGFRm NSCLC
Published: | Updated:
New data show amivantamab plus lazertinib boosts survival and brain control in EGFR+ lung cancer, with convenient Q4W injection tips.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
2
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
3
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
4
What Does the Future Hold for Immune Effector Cell Therapies?
5